Guide
Brand-Name vs Compounded
The single most consequential thing to understand before buying a GLP-1 online — and the thing the FDA has written to well over 100 telehealth companies about since September 2025.
The short version. Compounded semaglutide and tirzepatide contain the same active ingredient as Ozempic, Wegovy, Mounjaro and Zepbound. They are not the same products. They have not been approved by the FDA, have not been through the trials whose results are used to sell them, and are not evaluated by the FDA for safety, effectiveness or quality. Any provider that tells you otherwise is telling you something the FDA considers misbranding.
| Brand-name | Compounded | |
|---|---|---|
| FDA approval | Approved after review of safety, effectiveness and manufacturing quality | Not FDA-approved and not evaluated by the FDA for safety, effectiveness or quality |
| Clinical trials | STEP 1, SURMOUNT-1 and the rest were run on these exact products | No equivalent trials — shares an active ingredient, not an evidence base |
| Manufacturing oversight | FDA-inspected manufacturing under strict, standardised process control | 503A pharmacies compound per prescription; 503B outsourcing facilities are FDA-inspected but held to a different standard than drug manufacturing |
| Dose consistency | Standardised, verified batch to batch | Varies by pharmacy and formulation; independent testing has found real-world discrepancies |
| Typical US cash price | Often over $1,000/month without insurance | Commonly $69–$239/month |
| Insurance | May be covered, though weight-loss indications are frequently excluded | Essentially never covered |
| Additives | Fixed, disclosed formulation | Often blended with B12, glycine or other additives that were never in the trials |
Why The Rules Changed
The shortage window closed
The compounded GLP-1 industry grew up during a genuine shortage. Federal law generally bars compounding a product that is essentially a copy of a commercially available approved drug — but that restriction eases when the drug is in shortage. Tirzepatide came off the FDA shortage list in December 2024 and semaglutide in February 2025. Patient-specific compounding for a documented clinical need remains lawful; routinely producing copies of the commercial product does not. In April 2026 the FDA proposed excluding semaglutide, tirzepatide and liraglutide from the 503B bulk substances list, tightening things further.
The enforcement that followed
The FDA issued roughly 80 warning letters to telehealth and compounding operations in September 2025, around 30 more on 3 March 2026, and a further 25 during the week of 15 June 2026. The recurring allegation is the same: marketing that implies a compounded product is equivalent to, or is, an FDA-approved drug. Roughly a dozen providers reviewed on this site received one. Their reviews stay published — we simply keep them off our recommendation pages.
How To Tell An Honest Provider From A Misleading One
Good signs
- ✓States plainly, on the page you are buying from, that compounded medication is not FDA-approved
- ✓Names the compounding pharmacy and will tell you whether it is 503A or 503B
- ✓Cites efficacy figures with the trial and population attached, not as bare percentages
- ✓Can explain the clinical basis for compounding in your specific case
- ✓Also offers, or will refer you to, approved branded products
Warning signs
- ✕Describes its compounded product as "FDA-approved"
- ✕Says it contains "the same active ingredient as Ozempic" as though that settles equivalence
- ✕Prints its own logo on the medication label, implying it compounded the drug itself
- ✕Advertises oral tirzepatide — no approved oral tirzepatide product exists in any form
- ✕Quotes weight-loss rates trials never produced, such as "1.5% of body weight per week"
None of this means compounded medication is never a reasonable choice. For someone without coverage, facing a four-figure monthly cash price for the branded product, a well-run compounding platform may be the only realistic route to treatment — and several of the providers we rate highest are exactly that. It means going in with accurate expectations. See our compounded provider rankings and check your insurance first.
Keep reading
Medical Disclaimer: This page is for informational purposes only and does not constitute medical advice. Always consult a licensed healthcare provider before starting or changing any treatment. Compounded medications are not FDA-approved, are not evaluated by the FDA for safety, effectiveness or quality, and are not equivalent to the branded drug beyond sharing an active ingredient. GLP-1 medications commonly cause nausea, vomiting, diarrhoea and constipation, and carry risks including pancreatitis, gallbladder disease and kidney injury; they are contraindicated in people with a personal or family history of medullary thyroid carcinoma or MEN 2, and should not be used in pregnancy, when trying to conceive, or while breastfeeding. Prescribing is subject to clinician approval and is never guaranteed. Individual results vary and no outcome is promised.